A network of people with HIV urged the Thai authorities not to hand a multinational pharmaceutical company the rights to monopolise a drug to combat Hepatitis B as patients might have to pay millions of baht for the treatment.
At the Department of Intellectual Property (DIP) of the Ministry of Commerce, Bangkok, representatives of AIDs Access Foundation (AAF) and HIV positive people on Tuesday, 30 August 2016, handed a petition to the DIP urging it not to issue license for Sofosbuvir, a medicine for Hepatitis B treatment, to Gilead Sciences Company, an American biopharmaceutical cooperation, Thai Plus.Net reported.
The company requested the Thai authorities for the license of the medicine back in 2008.
Along with the petition, the group handed a 1000-page document to the DIP, saying that Article 31 of the Intellectual Property Act allows them to oppose the process to license the drug.
They pointed out that Sofosbuvir costs about 30,000 baht per a pill and that on average each patient in the US with Hepatitis B spend about 2.5 million baht on average for treatment with the medicine.
more HIV network opposes licensing of Hepatitis B pill costing 30,000 baht per pill | Prachatai English